BioSpace News Archive

The FDA has assigned a new Prescription Drug User Fee Act goal date of May 8, 2018.

The Company ended the quarter with €40 million in cash.

Senior executives from Voyager Therapeutics’ scientific, clinical and management team provided the highlights.

Corium’s fiscal year ends on September 30.

The study results reconfirm that Myring is bioequivalent to Nuvaring, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers.

The integration of N-of-One and Sunquest Mitogen will allow pathologists in hospitals and reference laboratories to streamline delivery of time-critical, case-specific genetic reports with high-quality clinical interpretation for NGS panels of all sizes.

These awards were granted pursuant to the Rigel PharmaInducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley acted as joint book-running managers for the offering.

A new real-world analysis of adults with type 2 diabetes and established CVD shows adult patients who initiated therapy with INVOKANA or another SGLT2i had a 43 percent reduced risk for ACM and hospitalization for HHF after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an ITT approach.

The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2017 financial results and provide a business update.